Overview

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses"

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of five doses of PBF-680 (5 mg, 10 mg, 20 mg, 40 mg and 60mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborator:
Palo Biofarma, S.L
Treatments:
Adenosine
Adenosine A1 Receptor Antagonists